Publication Details
Abstract
In order to develop effective anti-inflammatory agents for use in children, the pharmacological activity of Celagrip—a polymeric derivative of gossypol—was studied. It was established that Celagrip in immature rats significantly suppresses the intensity of aseptic inflammation induced by formalin, which is manifested by a reduction in the exudation process. In this respect, Celagrip is not inferior to the well-known nonsteroidal anti-inflammatory drug (NSAID), ibuprofen. In addition to its anti-inflammatory activity, Celagrip demonstrates pronounced antipyretic and analgesic effects. In terms of analgesic action, Celagrip is somewhat inferior to ibuprofen; however, it shows comparable antipyretic activity. It is believed that the mechanism underlying these effects of Celagrip is associated with its antioxidant properties, since, similar to Kagocel, it contains a polyphenolic compound in its molecular structure. After appropriate clinical trials, Celagrip may be used in pediatrics for the treatment of diseases in which aseptic inflammation plays an important role in the pathogenesis.